Strategic Priorities in Cancer Therapy: Navigating the 2026 Cancer Mission Calls
TBC
TBC
Show more
TBC
Monika Ślęzak
Monika joined Łukasiewicz – PORT in March 2022 as Coördinator of the Industry Contact Point for Medical Technologies and Health. She has over 10 years of research experience in molecular and cellular biology within the drug and vaccine development field, with a particular focus on preclinical studies, including in vitro and animal models such as mice and zebrafish.
She earned her PhD in 2009 from the Jagiellonian University in Kraków. Her doctoral dissertation focused on the genotoxic effects of acute carbon monoxide poisoning in humans. Since 2008, she has been involved in managing research projects funded by the European Union, including Horizon 2020, Horizon Europe, IMI, and IHI programs, serving as both project manager and research project leader. Since 2023, she has acted as an evaluator for competitions organized by the European Commission.
Show more
Her professional experience includes roles as project leader and senior scientist at Selvita S.A., one of the largest drug discovery companies in Central Europe, based in Kraków, as well as positions at the Molecular Biodiscovery Lab at KU Leuven in Belgium and the European Vaccine Initiative eV in Heidelberg, Germany.
She completed postgraduate studies in project management and research commercialization at the Cracow University of Economics (2011) and obtained the IPMA Project Manager Associate certificate the same year. In 2018, she completed specialized training in Good Clinical Practice through the CRA Training program at Pharmaakademie in Mannheim.
Read the Abstracts from Our Invited Speakers
Cancer Biology
- AllergoOncology: Lessons Learned from the Allergy-Glioblastoma Connection
Aurélie Poli, Luxembourg Institute of Health, LUXEMBOURG
- Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype
Joanna Poźniak, KU Leuven, BELGIUM
- Inducing Immunogenic Tertiary Lymphoid Structures Across Cancer Types With Dendritic Cell Reprogramming
Camille Chatelain, Lund University, SWEDEN
- The Role of ILC2 in Tissue Homeostasis and Neoplasia
Tim Halim, Cancer Research UK Cambridge Institute, UNITED KINGDOM
Cancer Neuroscience
- Latent Neuropathy in Colorectal Cancer: Implications for Cancer Survivorship
Andrew Shepherd, University of Texas MD Anderson Cancer Center, USA
- Remodelling of the Bone Microenvironment During Cancer Infiltration: Insights from Multiplex Imaging and Spatial Transcriptomics
Christina Møller Andreasen, University of Southern Denmark, DENMARK
- Enteric Nervous System-Derived VIP Restrains Differentiation of LGR5+ Stem Cells Towards the Secretory Lineage Impeding Type 2 Immune Programs
Christoph Klose, Charité – Berlin University Medicine, GERMANY
Cancer Therapy
- Targeting the Dark Matter of Cancer with AI-Designed Mini Binder
Tobias Bald, University of Bonn, GERMANY
- Engineering Nanomedicines for Targeted Neuroimmune Modulation
Helena Florindo, University of Lisbon, PORTUGAL
- Potentiating Immunotherapy of Urological Cancers with Oncolytic Viruses
Gabri van der Pluijm, Leiden University Medical Center, THE NETHERLANDS
- Strategic Priorities in Cancer Therapy: Navigating the 2026 Cancer Mission Calls
Industry Contact Point, Łukasiewicz – PORT, POLAND
- Cancer Neuroscience of Brain TumorsKEYNOTE SPEAKER
Frank Winkler, Universitätsklinik Heidelberg, GERMANY
- Spatial Reprogramming of Immune Surveillance in Breast Cancer: From Immune Control to Immune Failure
Sheeba Irshad, King’s College London, UNITED KINGDOM
- The War Against Glioblastoma Needs More Than Standard of Care
Stefaan Van Gool, IOZK Immun-Onkologisches Zentrum Köln, GERMANY
- Uncovering the Spatial Regulation of γδ T Cells: Toward Receptor-Guided Immunotherapy
Jürgen Kuball, University Medical Center Utrecht, THE NETHERLANDS
- CAR‑T Cell Therapy in Lymphomas, Acute Lymphoblastic Leukemia, and Multiple Myeloma
Wojciech Szlasa, DCOPIH, POLAND
- Expanding CAR Targets to Non Protein Antigens
Sébastien Wälchli, Oslo University Hospital, NORWAY
- Advancing BIA-ALCL Research Through a UK – PORT Alliance — From Biobanking to Immune Discovery
Helen Kakkassery, King’s College London, UNITED KINGDOM
PORT for Business — Company Session
- From Sample to Insight: Advanced Analytics for Oncology Research
Malwina Woźniak, Łukasiewicz – PORT, POLAND
- Beyond glioblastoma — WPD Pharmaceuticals
Marek Sipowicz, WPD Pharmaceuticals, POLAND
- The Development of USP7 Inhibitor for Cancer Immunotherapy
Zbigniew Zasłona, Molecule, POLAND
- Leveraging Cancer Biology for Therapeutic Innovation: Clinical and Discovery Advances at Ryvu
Milena Mazan, Ryvu Therapeutics, POLAND
- Transforming Multimodal Complexity into Precision Oncology Insights
Marek Kudła, Ardigen, POLAND
- JJP-1008 as a Novel Checkpoint Inhibitor
Agata Drewniak-Maksymów, JPP Biologics, POLAND
- Synergistic Nanotechnology for Targeted Therapeutics in Oncology
Artur Wnorowski, Biotechna, POLAND
- Development of Biological Drugs for Oncological Indications at Mabion
Jakub Knurek, Mabion, POLAND
- Enabling Early Drug Discovery: Integrated Screening Capabilities and a BRD4/CRBN PROTAC Case Study
Justyna Adamczyk, Enamine, POLAND